Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetRevenue - OtherRevenue - Rental
Ratios

Maxcyte (MXCT) Depreciation & Amortization (IS) (2021 - 2025)

Maxcyte (MXCT) has disclosed Depreciation & Amortization (IS) for 5 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (IS) rose 2.25% to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.2 million, a 0.45% change, with the full-year FY2024 number at $4.1 million, up 3.96% from a year prior.
  • Depreciation & Amortization (IS) was $1.0 million for Q3 2025 at Maxcyte, down from $1.1 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $1.1 million in Q2 2025 to a low of $311600.0 in Q1 2021.
  • A 5-year average of $799442.1 and a median of $977400.0 in 2023 define the central range for Depreciation & Amortization (IS).
  • Peak YoY movement for Depreciation & Amortization (IS): skyrocketed 128.96% in 2022, then decreased 4.05% in 2024.
  • Maxcyte's Depreciation & Amortization (IS) stood at $381600.0 in 2021, then surged by 128.96% to $873700.0 in 2022, then grew by 21.67% to $1.1 million in 2023, then decreased by 4.05% to $1.0 million in 2024, then grew by 2.35% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Depreciation & Amortization (IS) are $1.0 million (Q3 2025), $1.1 million (Q2 2025), and $1.1 million (Q1 2025).